This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Novartis' Immunotherapy Fails in Late-Stage Skin Cancer Study
by Zacks Equity Research
Novartis' (NVS) phase III study evaluating the investigational immunotherapy, spartalizumab, in combination with the targeted therapies, Tafinlar and Mekinist, fails to achieve goals.
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income - August 24, 2020
by Zacks Equity Research
The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Simple Secrets Anyone Can Use to Reach Early Retirement - August 21, 2020
by Zacks Equity Research
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
3 Strong, Diverse Dividend Stocks to Buy with Market at New Highs
by Benjamin Rains
It might be best to find stable stocks that offer solid dividend yields. So let's examine three highly-ranked stocks from three different industries that fit the bill...
The Extreme Risks of Trading Your Own Retirement Assets - August 19, 2020
by Zacks Equity Research
From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.
Opioid Crisis Deepens as Teva, Allergan Face Fraud Charges
by Kinjel Shah
The DFS charges claim that Teva (TEVA) and Allergan (AGN) used fraudulent marketing and promotional campaigns to promote their opioid products
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks - August 17, 2020
by Zacks Equity Research
The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
AbbVie (ABBV) is a Top Dividend Stock Right Now: Should You Buy?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
The Zacks Analyst Blog Highlights: Home Depot, AbbVie, Broadcom, 3M and Morgan Stanley
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Home Depot, AbbVie, Broadcom, 3M and Morgan Stanley
Easy Investing Secrets to an Early Retirement - August 13, 2020
by Zacks Equity Research
Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.
AbbVie Outperforms Large-Cap Pharma Industry Year to Date
by Zacks Equity Research
AbbVie's (ABBV) key drug, Humira is seeing strong demand in the United States while generics are eroding ex-U.S. sales. New drugs Skyrizi and Rinvoq are seeing strong sales uptake.
Top Analyst Reports for Home Depot, AbbVie & Broadcom
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including The Home Depot (HD), AbbVie (ABBV) and Broadcom (AVGO).
Large-Cap Pharma Industry Outlook Dull Amid Coronavirus Woes
by Kinjel Shah
The Zacks Large-Cap Pharmaceuticals industry ranks in the bottom 26% of more than 250 Zacks industries.
Reata (RETA) Q2 Earnings Top, Omaveloxolone Setback Hurts
by Zacks Equity Research
Reata (RETA) gets FDA recommendation to initiate a second study on omaveloxolone for additional data.
Signs That Your Trading Will Ruin Your Retirement - August 11, 2020
by Zacks Equity Research
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
Editas' (EDIT) Earnings Beat in Q2, Revenues Improve Y/Y
by Zacks Equity Research
Editas' (EDIT) both bottom and the top line better estimates for the second quarter of 2020.
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks - August 10, 2020
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Pharma Stock Roundup: ABBV, MRK Q2 Earnings & Coronavirus Updates in Focus
by Kinjel Shah
Sanofi (SNY)/Glaxo (GSK) and J&J (JNJ) sign deals with U.S. government for coronavirus vaccine candidate. Several drugmakers announce second-quarter results.
Ironwood (IRWD) Q2 Earnings Beat on Solid Linzess Sales
by Zacks Equity Research
Ironwood (IRWD) witnesses strong demand for Linzess in the second quarter. COVID-19 impacts enrollment in clinical studies.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Want To Retire Early? Learn the Intelligent Investing Secret - August 05, 2020
by Zacks Equity Research
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
3 Diverse Large-Cap Stocks to Buy Now to Boost Your Long-Term Portfolio
by Benjamin Rains
Investors should consider adding a few large-cap names that are prepared to grow for years to come. These three stocks also pay dividends and provide exposure to three very different and vital industries...
Signs That Your Trading Will Ruin Your Retirement - August 03, 2020
by Zacks Equity Research
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
ImmunoGen (IMGN) Q2 Earnings and Sales Beat, Shares Down
by Zacks Equity Research
ImmunoGen (IMGN) reports encouraging second-quarter results. Top-line data from pivotal study on its lead candidate, mirvetuximab soravtansine, likely to be delayed by six to eight weeks.
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income - August 03, 2020
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?